JP2016539172A - 癌標的化及び抗体作製のための抗ガングリオシド化合物 - Google Patents

癌標的化及び抗体作製のための抗ガングリオシド化合物 Download PDF

Info

Publication number
JP2016539172A
JP2016539172A JP2016536849A JP2016536849A JP2016539172A JP 2016539172 A JP2016539172 A JP 2016539172A JP 2016536849 A JP2016536849 A JP 2016536849A JP 2016536849 A JP2016536849 A JP 2016536849A JP 2016539172 A JP2016539172 A JP 2016539172A
Authority
JP
Japan
Prior art keywords
ganglioside
carbohydrate
cancer
cells
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016536849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539172A5 (enExample
Inventor
エイチ ウリ サラゴヴィ
エイチ ウリ サラゴヴィ
ウェンヨン トン
ウェンヨン トン
Original Assignee
ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ
ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ, ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ filed Critical ザ ロイヤル インスティチューション フォー ザ アドバンスメント オブ ラーニング／マギル ユニバーシティ
Publication of JP2016539172A publication Critical patent/JP2016539172A/ja
Publication of JP2016539172A5 publication Critical patent/JP2016539172A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2016536849A 2013-12-06 2014-12-04 癌標的化及び抗体作製のための抗ガングリオシド化合物 Pending JP2016539172A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361912684P 2013-12-06 2013-12-06
US61/912,684 2013-12-06
PCT/CA2014/051165 WO2015081438A1 (en) 2013-12-06 2014-12-04 Anti-ganglioside compound for targeting cancer and generating antibodies

Publications (2)

Publication Number Publication Date
JP2016539172A true JP2016539172A (ja) 2016-12-15
JP2016539172A5 JP2016539172A5 (enExample) 2017-03-09

Family

ID=53272688

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016536849A Pending JP2016539172A (ja) 2013-12-06 2014-12-04 癌標的化及び抗体作製のための抗ガングリオシド化合物

Country Status (7)

Country Link
US (1) US10363305B2 (enExample)
EP (2) EP3077405B1 (enExample)
JP (1) JP2016539172A (enExample)
CN (1) CN106414472A (enExample)
CA (1) CA2968995A1 (enExample)
ES (1) ES2904533T3 (enExample)
WO (1) WO2015081438A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018112669A1 (en) * 2016-12-23 2018-06-28 Realist Pharma, Inc. Ganglioside carbohydrate structures and uses thereof
KR20230155419A (ko) * 2020-10-05 2023-11-10 에이오에이 디엑스 암 진단을 위한 조성물 및 방법

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003073397A (ja) * 2001-08-30 2003-03-12 Wakamoto Pharmaceut Co Ltd 合成ムチン
JP2004518704A (ja) * 2000-11-29 2004-06-24 ブラッコ インターナショナル ビー．ヴイ． 結合能を有するシアリル・ルイスｘ類似物
JP2006347908A (ja) * 2005-06-14 2006-12-28 National Institute Of Advanced Industrial & Technology シアル酸含有３糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出
WO2007026669A1 (ja) * 2005-09-02 2007-03-08 Shizuoka Prefectural Universities Corporation ウイルスレセプター糖鎖認識特異性の判別方法
JP2008031156A (ja) * 2006-07-07 2008-02-14 National Univ Corp Shizuoka Univ 抗ウイルス剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221420B1 (en) * 1993-01-22 2002-09-28 Sloan Kettering Inst Cancer Ganglioside-protein conjugate vaccines
JP2004534088A (ja) * 2001-07-06 2004-11-11 スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ 癌のための多価コンジュゲートワクチン
WO2004041310A1 (en) * 2002-11-08 2004-05-21 Danmarks Fødevareforskning Preparation of chemically well-defined carbohydrate dendrimer conjugates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004518704A (ja) * 2000-11-29 2004-06-24 ブラッコ インターナショナル ビー．ヴイ． 結合能を有するシアリル・ルイスｘ類似物
JP2003073397A (ja) * 2001-08-30 2003-03-12 Wakamoto Pharmaceut Co Ltd 合成ムチン
JP2006347908A (ja) * 2005-06-14 2006-12-28 National Institute Of Advanced Industrial & Technology シアル酸含有３糖化合物、それを用いるサーズウイルスまたはサーズスパイク蛋白質の検出
WO2007026669A1 (ja) * 2005-09-02 2007-03-08 Shizuoka Prefectural Universities Corporation ウイルスレセプター糖鎖認識特異性の判別方法
JP2008031156A (ja) * 2006-07-07 2008-02-14 National Univ Corp Shizuoka Univ 抗ウイルス剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CARBOHYDRATE RESEARCH, vol. Vol.342(9), JPN6017033905, 2007, pages 1244 - 1248, ISSN: 0003708281 *
CARBOHYDRATE RESEARCH, vol. Vol.346(12), JPN6017033910, 2011, pages 1454 - 1466, ISSN: 0003708282 *
GLYCOCONJUGATE JOURNAL, vol. 14, JPN6017033912, 1997, pages 837 - 845, ISSN: 0003708283 *

Also Published As

Publication number Publication date
EP3077405B1 (en) 2021-11-03
EP3077405A4 (en) 2017-08-09
CN106414472A (zh) 2017-02-15
WO2015081438A1 (en) 2015-06-11
ES2904533T3 (es) 2022-04-05
US20160303227A1 (en) 2016-10-20
EP3077405A1 (en) 2016-10-12
CA2968995A1 (en) 2015-06-11
US10363305B2 (en) 2019-07-30
EP3957327A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
AU2015305332B2 (en) Novel glycan conjugates and use thereof
US9493580B2 (en) Multivalent glycopeptide constructs and uses thereof
US8835613B2 (en) β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
CA1337403C (en) Methods for the production of antibodies and induction of immune responses to tumor-associated gangliosides by immunization with ganglioside lactones
JP4713638B2 (ja) ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン
KR102167438B1 (ko) 변형된 당지질들 및 이들을 제조하고 사용하는 방법들
US20240042000A1 (en) Carbohydrate structures and uses thereof
JP2016539172A (ja) 癌標的化及び抗体作製のための抗ガングリオシド化合物
HK40064500A (en) Anti-ganglioside compound for targeting cancer and generating antibodies
Rashidijahanabad Development of Carbohydrate Based Conjugate Vaccines Using Qβ Virus Like Particles with Anti-bacterial or Anti-cancer Properties
Tong et al. A synthetic GD2 carbohydrate tetramer vaccine elicits tumor-killing antibodies and is therapeutic against GD2+ tumors
JP2011102320A (ja) ナチュラルキラーｔ細胞のリガンドと抗原を積載したｂ細胞を媒介とするワクチン

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170203

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20170214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170214

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170906

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20171206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180704

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180723